$LLY News

Forget Weight Loss Drugs: Here Is Another Reason to Buy Eli Lilly Stock

Lilly Strikes Up To $1.9 Billion Kidney Disease Gene Therapy Deal

Eli Lilly Retevmo Breakthrough Recasts Growth Story Beyond Obesity Treatments

Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations

Where Will Eli Lilly Stock be In 2028?

Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics

5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It’s Not AI)

NewLimit’s $435M megaround; Lilly’s busy dealmaking week

Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases

Getting Alzheimer’s Drugs Into the Brain Is Hard. Now There’s a New Trick.

Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas

Lilly, Ascidian link up in RNA exon editing pact

Lilly’s Van Naarden: Nothing is off the table for dealmaking

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down

Eli Lilly and Company’s (LLY) Foundayo and Zepbound Set To Be Covered for Millions of Americans

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

Eli Lilly To Highlight Phase 3 BRUIN CLL-322 Study Of Jaypirca, Non-Covalent Bruton Tyrosine Kinase Inhibitor, As Part Of Time-Limited Regimen For Patients With Previously Treated Chronic Lymphocytic Leukemia, At EHA Annual Meeting

PBM Coverage Of Eli Lilly Obesity Drugs Reshapes Growth And Pricing Outlook